Latest From Agendia BV
How much therapies should cost and how they should be reimbursed are questions that are expected to dominate in 2019, according to industry experts and participants interviewed by Scrip on their expectations for the coming year. This is the focus for the final installment of our three-part Scrip Asks series.
Scrip journalists asked industry executives, consultants and analysts what they believe the big themes, trends and events will be in 2019. Here's what they told us about advances in therapeutic technologies and areas of clinical innovation.
Results of the MINDACT trial, which show that Agendia BV's MammaPrint 70-gene lab test can identify about half of the early-stage breast cancer patients who do not need chemotherapy, has led the American Society of Clinical Oncology to specifically recommend the test in its guidelines.
This week’s roundup includes the appointment of Sanofi Genzyme’s executive vice president and various high-level appointments by companies including Recipharm, e-Therapeutics, Diplomat Pharmacy and Axovant.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Agendia BV
- Senior Management
Mark R Straley, CEO
Kurt Becker, CFO & COO
Chris Barbazette, Chief Commercial Officer
William Audeh, MD, CMO
René Bernards, PhD, CSO
Bastiaan van der Baan, Chief Clinical & Bus. Dev. Officer
- Contact Info
Phone: 20 462 1500
Science Park 406
Amsterdam, CA 1098 XH
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.